QUOTE(ngaisteve1 @ Dec 5 2014, 02:23 AM)
tham, should thalassemia people exercise?
Since anemic patients have a reduced exercise capacity and
reduced heart performace, you should try moderate and not
heavy, strenuous exercise, such as light jogging and walking.
The main goal is to keep iron overload to a minimum.
Have you tried EDTA chelation therapy to reduce your iron ?
There are quite a few doctors here practising EDTA chelation,
but it doesn't come cheap - at least $200 - 300 per session.
Exercise limitation, exercise testing and exercise
recommendations in sickle cell anemia.
'' Therefore, patients are advised to start exercise slowly and progressively,
to maintain adequate hydration during and after exercise, to avoid cold
exposure or sudden change in temperature, and to avoid sports associated
with mechanical trauma. ''
http://www.ncbi.nlm.nih.gov/m/pubmed/22214686/Running exercise alleviates trabecular bone loss and osteopenia
in hemizygous β-globin knockout thalassemic mice.
'' A decrease in BMD was more severe in female than in male BKO mice. ''
'' Several histomorphometric parameters suggested an enhancement of bone
formation (e.g., increased mineral apposition rate) and suppression of bone resorption
(e.g., decreased osteoclast surface), which led to increases in trabecular
bone volume and trabecular thickness in running BKO mice. ''
'' .... running exercise appeared to be an effective intervention in alleviating
bone microstructural defect in β-thalassemia. ''
http://www.ncbi.nlm.nih.gov/m/pubmed/24780610/Exercise performance in thalassemia major:
correlation with cardiac iron burden.
http://www.ncbi.nlm.nih.gov/m/pubmed/23339082Iron overload in β-thalassemia intermedia: an emerging concern.
http://www.ncbi.nlm.nih.gov/m/pubmed/23426199/Better survival and less cardiac morbidity in female patients
with thalassemia major: a review of the literature.
http://www.ncbi.nlm.nih.gov/m/pubmed/20712783/Oral chelators in transfusion-dependent thalassemia major
patients may prevent or reverse iron overload complications.
'' The hypothesis of this study was that combining two oral chelators,
deferiprone and deferasirox, might lead to similar results. ''
'' Regarding the safety assessment, the incidence of adverse events was minor
compared to the associated toxicity of monotherapy of each drug. No new
onset of iron overload-related complications was demonstrated. A reversal
of cardiac dysfunction was observed in 2/4 patients, while the mean LVEF
increased significantly. ''
http://www.ncbi.nlm.nih.gov/m/pubmed/21531154Increased survival and reversion of iron-induced cardiac disease
in patients with thalassemia major receiving intensive combined
chelation therapy as compared to desferoxamine alone.
http://www.ncbi.nlm.nih.gov/m/pubmed/20678715/Improving survival with deferiprone treatment in patients with thalassemia major:
a prospective multicenter randomised clinical trial under the auspices of the
Italian Society for Thalassemia and Hemoglobinopathies.
'' ..... mortality, due mainly to cardiac damage, was reduced or completely
absent in patients treated with deferiprone (DFP) alone or a combined
deferiprone-deferoxamine (DFP-DFO) chelation treatment. ''
http://www.ncbi.nlm.nih.gov/m/pubmed/19233692/Increased survival and reversion of iron-induced cardiac disease in patients
with thalassemia major receiving intensive combined chelation therapy as
compared to desferoxamine alone.
http://www.ncbi.nlm.nih.gov/m/pubmed/20678715Cardiac and hepatic iron and ejection fraction in thalassemia major:
multicentre prospective comparison of combined deferiprone and d
eferoxamine therapy against deferiprone or deferoxamine monotherapy.
'' Among the patients with hepatic iron at baseline, the decrease in liver
iron concentration values was significantly higher with combination
therapy than with either monotherapy group. ''
http://www.ncbi.nlm.nih.gov/m/pubmed/23324167/This post has been edited by Tham: Dec 6 2014, 12:25 AM